Yesterday I attended the Annual General Meeting of Bioventix Plc at the Mercure Bush hotel, Farnham, Surrey. Bioventix is a small (market Cap is £64.5 million) company that specialises in the development and commercial supply of high-affinity monoclonal antibodies with a focus on their application in clinical diagnostics. Results for the year ended 30th June 2015 were as follows: Revenues up 23% to £4.3 million, profit up 39% to £3.1 million and cash balances up £780k to £4.13m. Much of this revenue growth was down to the vitamin D antibody in the form of both physical sales and royalties. With approximately 12 shareholders present, the Chairman Ian Nicholson opened the meeting, acknowledging the number of shareholders that had made the effort to attend, a record for the company I believe.
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.